Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 10/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860115 | 0.89 | AKT1 (0.50) | MALT1CMA1TACR1AKT1 | |
| SCHEMBL5579737 | 0.89 | TACR1 (0.43) | TACR1FKBP4 | |
| SCHEMBL6746799 | 0.89 | CMA1 (0.49) | CMA1 | |
| SCHEMBL30561151 | 0.85 | OPRM1 (0.47) | TACR1FKBP4OPRM1OPRK1 | |
| SCHEMBL7586649 | 0.85 | OPRM1 (0.47) | TACR1FKBP4OPRM1OPRK1 | |
| SCHEMBL18619572 | 0.84 | MALT1 (0.64) | MALT1CMA1EPHA2 | |
| SCHEMBL18621052 | 0.84 | MALT1 (0.64) | MALT1CMA1EPHA2 | |
| SCHEMBL22811073 | 0.84 | MALT1 (0.64) | MALT1CMA1EPHA2 | |
| SCHEMBL22209365 | 0.84 | MALT1 (0.64) | MALT1CMA1EPHA2 | |
| SCHEMBL1087489 | 0.84 | KDM1A (0.50) | TACR1FKBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540944-B2 | Recombinant amebocyte clotting factors and uses thereof | CHARLES RIVER LABORATORIES, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250085289-A1 | RECOMBINANT AMEBOCYTE CLOTTING FACTORS AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. | 2025-03-13 | — | — | US | disclosed |
| US-12158471-B2 | Recombinant amebocyte lysate and uses thereof | CHARLES RIVER LABORATORIES, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240125789-A1 | HYBRID AMEBOCYTE LYSATE AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4291648-A1 | HYBRID AMEBOCYTE LYSATE AND USES THEREOF | Charles River Laboratories, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230258647-A1 | HYBRID AMEBOCYTE LYSATE AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2023-08-17 | — | — | US | disclosed |
| WO-2022174082-A1 | HYBRID AMEBOCYTE LYSATE AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540944-B2 | Recombinant amebocyte clotting factors and uses thereof | F13B, FGB, F5 | MALT1 3388/4885CMA1 2267/4885EPHA2 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.